+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Ifinatamab Deruxtecan I-DXd compared to the treatment chosen by a physician for people with relapsed small cell lung cancer SCLC. This Phase 3 study aims to see if I-DXd can help participants live longer than current treatments, while also examining other effects such as patient-reported outcomes, immune response, and the drugs behavior in the body. Participants will be randomly assigned to one of two groups. One group will receive I-DXd as an intravenous infusion at a dose of 12 mgkg every 21 days until the disease worsens, unacceptable side effects occur, or other stopping reasons arise. The other group will receive one of the standard treatments chosen by their doctortopotecan, lurbinectedin, or amrubicinaccording to local approved dosing guidelines and until treatment discontinuation criteria are met. During the study, participants will be closely monitored with regular imaging and assessments to track tumor response, disease progression, and quality of life using questionnaires. Safety events and immune responses will also be recorded. Pharmacokinetic samples will be collected at specified times to understand how I-DXd behaves in the body. Participants may remain in the study for up to approximately 3.7 years, allowing for long-term evaluation of outcomes and safety.

Age: 18Years +All GendersPhase 3
229 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of Pumitamig compared to Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer NSCLC who have a PD-L1 expression of 50% or higher. This Phase 3, randomized, double-blind study focuses on participants with locally advanced or metastatic NSCLC, aiming to understand which treatment better controls the disease and improves survival outcomes. Participants are randomly assigned to receive either Pumitamig or Pembrolizumab at specified doses on specified days. The study compares these two drugs as first-line treatments for their impact on disease progression and overall survival. The treatment period may last up to approximately five years to assess long-term outcomes. During the study, participants will undergo regular assessments including imaging and symptom questionnaires to evaluate progression-free survival and overall survival. Researchers will also monitor objective response, duration of response, disease control rate, and symptom changes using established criteria. Safety and effectiveness will be closely followed throughout the study, which lasts up to about five years from enrollment.

Age: 18Years +All GendersPhase 3
283 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the impact of adding digital checkboxes to the electronic triage system in an emergency department to improve patient flow and reduce the total length of stay. This before-and-after observational study compares patient throughput during a pre-intervention phase from May 1st to July 31st, 2026, with a post-intervention phase during the same months in 2027 to minimize seasonal effects. The primary focus is on the total Emergency Department Length of Stay ED LOS. The intervention involves introducing digital anticipatory protocols at triage, which provide nurses with structured options for expected patient management based on acuity. During the pre-intervention phase, patients undergo the standard triage assessment using the Swiss Emergency Triage Scale, while the post-intervention phase adds the digital checkboxes. Patient disposition decisions are tracked using digital tags in electronic health records throughout both phases. Participants are patients aged 18 years and older who register at the emergency department admission desk during the study periods. Researchers monitor outcomes such as total ED length of stay, patients who leave without being seen, 30-day mortality, and transfers to intensive care units. The study observes participants through completion of the ED visit, up to a maximum of 72 hours, with some outcomes followed up to 30 days or 7 days post-visit. This allows assessment of patient flow improvements and safety over time.

Age: 18Years +All Genders
1 location
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer NSCLC who have a KRAS G12C mutation. The study includes both Phase 2 and Phase 3 portions, focusing on patients eligible for first-line treatment with varying levels of PD-L1 expression. The trial compares adagrasib combined with pembrolizumab to pembrolizumab alone in patients with high PD-L1 expression. In Phase 2, patients are divided into three groups based on PD-L1 TPS scores two groups with scores below 1% receive either adagrasib monotherapy or adagrasib plus pembrolizumab, and one group with scores of 1% or higher receives the combination. Phase 3 randomizes patients with PD-L1 TPS of 50% or higher to receive either adagrasib plus pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given intravenously every three weeks. Participants undergo regular assessments including brain imaging, tumor measurements, and quality of life questionnaires. Researchers monitor treatment effects, safety, drug levels in blood, and lung cancer symptoms over periods of up to 22 months in Phase 2 and 36 months in Phase 3. The study also evaluates progression-free survival, response duration, and other outcomes to understand the treatments impact.

Age: 18Years +All GendersPhase 2Phase 3
770 locations
S

Actively Recruiting

Researchers are studying primary and acquired resistance mechanisms to standard treatments targeting BRAF V600E mutations in metastatic colorectal cancer. This observational study focuses on patients receiving combined therapy with BRAF inhibitor encorafenib, anti-EGFR antibody cetuximab, and chemotherapy. Resistance to this combination often develops, limiting treatment options, so the study aims to uncover genetic and non-genetic reasons behind this resistance to help develop better future therapies. Participants will receive standard-of-care treatment with encorafenib, cetuximab, and possibly chemotherapy. Before starting treatment and at the time of disease progression, researchers will collect tumor tissue, blood, and stool samples. These samples will be used to study molecular changes and the microbiome, and to create patient-derived organoids for laboratory testing. Blood samples will be collected regularly during treatment to analyze circulating tumor DNA over time. Throughout the study, participants will be followed longitudinally with sample collections before treatment and at progression, continuing for up to around 24 months. Researchers will measure molecular alterations linked to resistance, compare tissue and liquid biopsy findings, characterize gut microbiome changes, and track tumor DNA dynamics. The studys findings aim to improve understanding of resistance and support personalized treatment approaches for metastatic colorectal cancer.

Age: 18Years +All Genders
13 locations
S

Actively Recruiting

Healthy Volunteer

This research aims to evaluate whether reinforcing the abdominal wall with a mesh during closure after open abdominal aortic aneurysm AAA repair can prevent incisional hernias IH. The study is retrospective and observational, focusing on patients who had this mesh reinforcement technique between 2019 and 2024. Researchers want to understand if mesh use reduces hernia rates and how often related postoperative complications occur compared to cases without mesh reported in the literature. The treatment studied is prophylactic retromuscular mesh reinforcement, where a mesh is placed behind the rectus abdominis muscles during abdominal closure to strengthen the wall and reduce hernia risk. This is done by carefully dissecting muscle layers and placing a self-gripping polyester or composite mesh extending beyond the midline without tension. The mesh is secured and the abdominal layers are sutured closed. The study looks at patients treated at one hospital over several years with this technique. Participants underwent clinical follow-ups and abdominal ultrasounds to detect incisional hernias. They also completed quality-of-life questionnaires including EQ-5D and PROMIS. The primary outcome measured is the rate of incisional hernias within a specific timeframe January to April 2025. Secondary outcomes include rates of complications such as fascial dehiscence, seromas, surgical site infections, hematomas, and operative time. The study relies on reviewing medical records and follow-up data from at least one year after surgery.

Age: 18Years +All Genders
1 location
S

Actively Recruiting

Researchers are studying a new drug called ALE.F02 to see if it can protect and preserve kidney function in people with antineutrophil cytoplasmic antibody ANCA associated vasculitis AAV. AAV is an autoimmune disease where the bodys immune system attacks small blood vessels, often affecting the kidneys. This Phase 2 trial aims to evaluate the safety, tolerability, and kidney-protective effects of ALE.F02 when added to standard therapy for rapidly progressive glomerulonephritis RPGN caused by AAV. Participants will be randomly assigned to one of four groups standard treatment plus low, high, or maximum dose ALE.F02 infusions, or standard treatment plus placebo infusions. The treatment period lasts 24 weeks, during which participants receive 13 intravenous infusions alongside standard therapies like Rituximab, glucocorticoids, or cyclophosphamide. The study includes detailed monitoring such as blood and urine tests, pharmacokinetics, antidrug antibody testing, biomarker measurements, pregnancy tests for women, and lung CT scans at baseline and Week 24 if lung involvement is detected. During the study, participants will undergo physical exams and provide samples to assess kidney function and safety. Researchers will measure the primary outcome of safety and tolerability of ALE.F02 up to one year. Secondary outcomes include changes in kidney function markers like estimated glomerular filtration rate eGFR and urine protein levels up to 52 weeks. Participants exposure to glucocorticoids and immunosuppressants will also be tracked. The total study duration extends through treatment and follow-up, with ongoing assessments to understand the drugs effects and safety profile.

Age: 18Years +All GendersPhase 2
53 locations